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Introduction: High expression of aldehyde dehydrogenase1A1 (ALDH1A1) is observed in many organs and tumors
and may identify benign and cancer stem cell populations.
Methods: In the current study, the stem cell characteristics were determined in cells isolated from human prostate
cell lines and clinical prostate specimens based upon the ALDEFLUOR™ assay. Cells isolated based on the
ALDEFLUOR™ assay were compared to cells isolated based on ATP binding cassette transporter G2 (ABCG2) activity
using the side population assay. To test for stem cell characteristics of self-renewal and multipotency, cells with high
and low ALDH1A1 activity, based on the ALDEFLUOR™ assay (ALDHHi and ALDHLow), were isolated from prostate
clinical specimens and were recombined with rat urogenital sinus mesenchyme to induce prostate gland formation.
Results: The percentage of ALDHHi cells in prostate cell lines (RWPE-1, RWPE-2, CWR-R1, and DU-145) was 0.5 to 6%,
similarly in non-tumor and tumor clinical specimens the percentage of ALDHHi cells was 0.6 to 4%. Recombinants
using ALDHHi cells serially generated prostate tissue up to three generations with as few as 250 starting cells.
Immunohistochemical analysis of the recombinants using ALDHHi cells contained prostatic glands frequently
expressing androgen receptor (AR), p63, chromogranin A, ALDH1A1, ABCG2, and prostate specific antigen (PSA),
compared to their ALDHLow counterparts. Inhibition of ALDH resulted in the reduction of sphere formation
capabilities in the CWR-R1, but not in the RWPE-2 and DU-145, prostate cell lines. ABCG2 inhibition resulted in a
more robust decrease of sphere formation in androgen sensitive cell lines, CWR-R1 and RWPE-2, but not androgen
insensitive DU-145. ALDH1A1 expression was enriched in ALDHHi cells and non-side population cells. ABCG2
expression was only enriched in side population cells.
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Conclusions: The percentage of ALDHHi cells in prostate cell lines and prostate tissue was consistently higher
compared to cells with high ABCG2 activity, identified with the side population assay. The expression of the stem
and differentiation markers indicates the ALDHHi recombinants contained cells with self-renewal and multipotency
activity. When the two assays were directly compared, cells with the side population phenotype demonstrated
more stem cell potential in the tissue recombination assay compared to ALDHHi cells. The increased stem cell
potential of side population cells in the tissue recombination assay and the decrease in sphere formation when
ABCG2 is inhibited indicates that the side population enriches for prostate stem cells.Introduction
Cytoprotective activity is proposed to protect stem cells
from mutations that can arise from cytotoxic insults.
Therefore, stem cells are often isolated based on cyto-
protective activity. Conversely, stem cell assays have been
developed exploiting a cytoprotective mechanism. Two
examples of assays based on stem cell cytoprotective activ-
ity are: (1) the side population assay based on the efflux of
Hoechst 33342 fluorescent dye by the ATP-binding cas-
sette (ABC) transporters [1] and; (2) high activity of al-
dehyde dehydrogenases (ALDH) detoxifying enzymes [2].
The ALDEFLUOR™ assay was developed based on the sec-
ond property [2]. ABC transporters remove cytotoxins
and regulatory signals (Reviewed in [3]). ALDHs catalyze
the irreversible oxidation of several different endogenously
and exogenously produced aldehydes into the correspond-
ing carboxylic acids (Reviewed in [4]).
The human ALDH superfamily consists of 19 mem-
bers where ALDH1A1 and ALDH3A1 are thought to be
important in stem cell protection, differentiation and ex-
pansion [2,4-7]. Members of the ALDH family have been
identified as markers for both normal and cancer stem
cells in different tissues [4-7]. Specifically, ALDH1A1
and ALDH3A1 have been used as markers to isolate nor-
mal and cancer stem cells and have a potential functional
role in normal and cancer stem cells (Reviewed in [4]).
Van den Hoogen et al. determined expression of several
ALDH enzyme isoforms in primary prostate tumors and
primary prostate cultures and expression of ALDH1A1,
ALDH4A1, ALDH7A1 and ALDH9A1 were elevated [8].
ALDH activity is emerging as a promising marker that can
be used to identify and isolate normal and cancer stem
cells [9].
The ALDEFLUOR™ assay is based on the conversion of
Bodipy aminoacetaldehyde (BAAA), an ALDH substrate,
to highly fluorescent Bodipy aminoacetate (BAA). Thus,
cells with high ALDH1A1 activity (ALDHHi) can be iso-
lated using fluorescence activated cell sorting (FACS) [2].
High levels of ALDH expression and activity in stem cells
from various cancers including bladder, breast, lung, ovar-
ian, liver, colon, pancreas and prostate have been detected
using the ALDEFLUOR™ assay [10-18]. High ALDH1A1
activity is associated with poor prognosis in patients withbreast and prostate cancer [18,19]. Li et al. found that high
ALDH1A1 expression in clinical prostate specimens
correlated with poor prostate cancer patient survival and
Gleason Score [18]. The studies also tested the tumorigen-
icity of ALDHHi and ALDHLow cells isolated from LNCaP
and PC-3 prostate cancer cell lines. A minimum of 500
ALDHHi cells from LNCaP and PC-3 prostate cancer cell
lines generated serially transplantable prostate tumors
containing neuroendocrine and secretory cells, suggesting
multipotentiality [18]. In separate studies, as few as 100
ALDHHi cells from the PC-3 M cell line had tumor
forming and metastatic ability [8]. ALDHHi cells isolated
from epithelial ovarian cancer cell lines are shown to have
more sphere-forming capabilities, are more tumorigenic,
and contribute to chemotherapy resistance as compared
to ALDHLow cells. This suggests that ALDHHi cells are
enriched for cancer stem-like cells [20]. The inhibition of
ALDH1, with diethylaminobenzaldehyde (DEAB), reduced
cancer stem cell characteristics of chemotherapy and radi-
ation resistance in ALDHHi breast cancer cells [21].
In cell lines from different cancer types, ALDHHi cells
have higher sphere formation ability, tumorigenicity
and are more chemo- and radio-resistant compared to
ALDHLow cells. However, ALDHHi cells have not been
isolated from clinical specimens of prostate cancer, or
tested in prostate stem cell assays. In the current study,
we tested ALDHHi cells isolated from cell lines and
human prostate specimens for stem cell properties.
ALDHHi and ALDHLow cells from clinical specimens
were evaluated for stem cell characteristics using tissue
recombination with rat urogenital mesenchyme (rUGM)
for serial prostate regenerative capability compared to
cells isolated based on the side population assay. The
requirement for ALDH and ABCG2 activity was deter-
mined in the sphere formation assay.
Methods
Ethics statement
All of the tissue samples were collected under an Institu-
tional Review Board (IRB)-approved exempt non-human
research protocol at Roswell Park Cancer Institute (RPCI).
Specimens were collected after IRB-approved written
consent from the patient was obtained at RPCI. All
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Institutional Animal Care and Use Committee (IACUC)
at RPCI under protocol ID number 1201 M.
Cell lines and culture
Prostate cell lines RWPE-1 American Type Culture Col-
lection (ATCC, Manassas, VA, USA), RWPE-2 (ATCC),
CWR-R1 and DU-145 were maintained in culture medium
as described previously [22]. Briefly, RWPE-1 and RWPE-2
cells were maintained in Keratinocyte Serum Free
Medium supplemented with bovine pituitary extract and
epidermal growth factor. DU-145 cells were maintained
in Roswell Park Memorial Institute (RPMI) 1640 media
supplemented with 10% FBS, L-glutamine, penicillin and
streptomycin. CWR-R1 cells were maintained in Richter’s
improved MEM supplemented with 2% FBS, HEPES, ITS,
epidermal growth factor, linoleic acid and nicotinamide.
All cell lines were cultured at 37°C in an atmosphere of
5% CO2. Cells were grown to 90% confluence and har-
vested by incubation with trypsin-EDTA.
Human prostate clinical specimen digestion
Fresh human benign prostate tissue and prostate cancer tis-
sue (>90% cancer), identified by analysis of frozen sections
from radical prostatectomy surgical specimens, was ob-
tained from the Pathology Resource Network at RPCI as
described previously [23]. All prostate tissue was obtained
in accordance with National Institutes of Health (NIH)
guidelines on the use of human subjects and with the ap-
proval of the RPCI Internal Research Board. Enzymatic
tissue digestion with dispase and single cell suspension
preparation was performed as described previously [22,24].
Gating strategy used for FACS isolation of ALDHHi and
ALDHLow cells
Cells isolated from prostate tissue were stained with the
ALDEFLUOR™ reagent from the ALDEFLUOR™ assay kit
(Stem Cell Technologies, Vancouver, BC, Canada) ac-
cording to the manufacturer’s protocol and as previ-
ously described [2,13]. The assay was optimized to
interact with human ALDH1A1 according to the man-
ufacturer’s protocol and as previously described [2,13].
Briefly, the isolated cells were stained with 1 μM
ALDEFLUOR™ reagent and incubated at 37°C for 45 to
60 minutes. RWPE-1 and RWPE-2 prostate cells were
stained with 0.1 μM ALDEFLUOR™ reagent. CWR-R1
and DU-145 prostate cells were stained with 0.5 μM
ALDEFLUOR™ reagent. After incubation, the cells were
centrifuged at 950 × g and resuspended in 0.5 ml
ALDEFLUOR™ assay buffer. The cells were labeled with
7-aminoactinomycin D (7-AAD) at a concentration of
5 μl/500 μl to eliminate dead cells. Cells were sorted
into ALDHHi and ALDHLow populations with a BD FACS
Aria II cell sorter (BD Bioscience, San Jose, CA, USA).Cells with high fluorescence indicate high ALDH1A1
activity, ALDHHi cells, were detected and the dead cells
were eliminated using 7-AAD. DEAB (15 μM), a potent
inhibitor of ALDH1 activity, was added to establish the
ALDHHi population. Forward scatter and side scatter plots
were used to reduce gating doublets and obtain a singlet
population.
Gating strategy used for FACS isolation of side
population and non-side population cells
Cells isolated from prostate tissue were stained with 10 μM
Vybrant® DyeCycle™ Violet (DCV) (Invitrogen, Carlsbad,
CA, USA) according to a protocol modified from Telford
et al. [25] and 7-AAD as previously described [22,26]. The
gating strategy for sorting the side and non-side popula-
tions was performed as previously described [22,26]. Viable
cells were sorted based upon DCV content into side and
non-side populations with a BD FACS Aria II cell sorter.
Sphere formation assay
The sphere formation assay was performed with RWPE-2,
CWR-R1 and DU-145 prostate cells by treatment in the
presence of 5, 10 and 20 μM DEAB or 1 and 5 μM Ko143.
DEAB was prepared in 95% EtOH, and Ko143 was pre-
pared in DMSO. ETOH (95% EtOH) or DMSO treatment
was used as the vehicle control. Cells were plated at a
density of 5,000 cells/well in ultra-low attachment 24-well
plates (VWR-Cat # 29443–032, Radnor, PA, USA) in
quadruplicate, and the experiment was performed two
times. Cells were suspended in 40 μL medium and mixed
thoroughly with 60 μL BD Matrigel™ (BD Bioscience, San
Jose, CA, USA, Cat # 354234,). The mixture was pipetted
around the rim of the well, and the plate was incubated in
a 5% CO2 incubator at 37°C for 45 minutes to allow the
BD Matrigel™ to solidify. A total of 900 μL of appropriate
media was added to each well and plates were maintained
in 5% CO2 incubator at 37°C for 10 to 14 days. Spheres in
each well were quantitated after 10 to 14 days visually
under a microscope at 10× magnification.
RNA isolation and cDNA synthesis
RNA isolated from the side population, non-side popula-
tion, ALDHHi and ALDHLow cells CWR-R1 prostate can-
cer cells was used to determine the expression of ABCG2
and ALDH1 genes. RNA was isolated using RNAeasy
micro kit (Qiagen, Valencia, CA, USA, Cat # 74004) ac-
cording to the manufacturer’s protocol, and the concen-
tration of total RNA was determined using the NanoDrop
8000 spectrophotometer (Wilmington, DE, USA). Total
RNA (50 ng) from each sample was reverse transcribed
into single-stranded cDNA with a SuperScript III First-
Strand cDNA synthesis kit (Invitrogen, Carlsbad, CA,
USA, Cat, # 18080–051) using oligo (dT) primers, accor-
ding to the manufacturer’s protocol.
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Real-time PCR was performed to determine gene expres-
sion. The synthesized cDNA was amplified by real-time
PCR using a SYBR Green master mix kit (Applied Biosys-
tems, Carlsbad, CA, USA, Cat # 4309155). The reactions
were carried out in a total volume of 20 μL. Analyses for
ABCG2, ALDH1A1, ALDH4A1, ALDH7A1, ALDH9A1
and GAPDH were performed. Conditions for the PCR
were: 50°C for 2 minutes, 95°C for 10 minutes, followed
by 40 cycles each run at 95°C for 15 seconds and 60°C for
1 minute. The primers (Integrated DNA Technologies,
Coralville, IA, USA) used were: ABCG2 (0.25 μM) sense,
5′ – AGCAGGATAAGCCACTCATAGA – 3′;
ABCG2 (0.25 μM) antisense, 5′ –
GTTGGTCGTCAGGAAGAAGAG – 3′;
ALDH1A1 (0.5 μM) sense, 5′ –
TTACCTGTCCTACTCACCGATT – 3′;
ALDH1A1 (0.5 μM) antisense, 5′ –
GCCTTGTCAACATCCTCCTTAT – 3′;
ALDH4A1 (0.5 μM) sense, 5′ –
GGACGTGCAGTACCAAGTGT – 3′;
ALDH4A1 (0.5 μM) antisense, 5′ –
TAGGCTTCAGGTCCCACTCT – 3′;
ALDH7A1 (0.5 μM) sense, 5′ –
CAACGAGCCAATAGCAAGAG – 3′;
ALDH7A1 (0.5 μM) antisense, 5′ –
GCATCGCCAATCTGTCTTAC – 3′;
ALDH9A1 (0.5 μM) sense, 5′ –
GCTGCCAGGATAATAAGGGA – 3′;
ALDH9A1 (0.5 μM) antisense, 5′ –
GAAATGTCAATGTCCAAGCG – 3′;
GAPDH (0.2 μM) sense, 5′ –
GAACATCATCCCTGCCTCTACT – 3′;
GAPDH (0.2 μM) antisense, 5′ –
CGCCTGCTTCACCACCTT -3′.
Reactions were run and analyzed using an Applied Bio-
systems 7300 fast real-time PCR system (Carlsbad, CA,
USA). Gene expression was normalized to GAPDH and
fold change in gene expression was calculated using the
following formula: fold change in gene expression = 2-(ΔΔdCt).
Tissue recombinant technique
Rat urogenital sinus mesenchyme was dissected as de-
scribed previously [27,28]. First generation recombinants
were made by aliquoting 50 to 2,000 ALDHHi or ALDHLow
cells or 50 to 250 side population or non-side population
cells isolated from human prostate tissue specimens with
a single rUGM in a 200 μL microcentrifuge tube. Sorted
cells were spun onto the rUGM, or in a separate tube
sorted cells were pelleted alone as a negative control.
Sorted cells + rUGM and sorted cell pellets were sus-
pended in collagen as described previously [26].Renal grafting
Cells plus rUGM or cells alone in collagen were grafted
under the renal capsule in 12-week-old SCID male
CbySmn. CB 17 Prkdcscid mice, which were castrated
and implanted subcutaneously with 12.5 mg sustained-
release testosterone pellets (Innovative Research of
America, Sarasota, FL, USA) as described previously
[26]. Following 6 to 12 weeks of growth, grafts were har-
vested and weighed. When ductal growth was present,
grafts were micro-dissected and a portion was used for
serial recombination with new rUGM as described previ-
ously [26]. Briefly, an approximately 1 mm cube of tissue
containing both epithelial and stromal compartments was
micro-dissected from the graft and used for serial recom-
bination with new rUGM [26]. The remaining portion of
the recombinant was fixed in neutral buffered formalin as
described previously [26].
Identification of the origin of prostate generated using
fluorescence in situ hybridization (FISH)
In order to identify the cells contributing to the prostate
epithelium in the tissue recombinants FISH was per-
formed (Additional file 1: Figure S1). Mammalian telo-
meres were detected as described previously [26]. The
number of human prostatic glands in each recombinant
was determined as previously described [26].
Immunohistochemistry (IHC)
Immunohistochemical analysis was performed to exam-
ine the expression of prostate differentiation markers as
described previously [26]. ALDH1A1 was detected using
a 1:80 dilution of rabbit monoclonal anti-ALDH1A1
(cat # NB110-55451, Novus Biologicals, Littleton, CO,
USA). Human prostate tissue served as a positive control,
and no primary antibody controls served as negative
controls in all experiments (Additional file 2: Figure S2).
Aperio imaging recombinant histology and IHC
All slides containing stained recombinants were scanned
on the ScanScope XT System in the Pathology Resource
Network (Buffalo, NY, USA) at RPCI, and images were ana-
lyzed with Spectrum Version 10.2.2.2317 (Vista, CA, USA).
Statistical analysis
Fisher’s exact test, Student’s t-test and One-way ANOVA
were performed with GraphPad Prism version 6.00 soft-
ware (La Jolla, CA, USA). The recombinant survival rate
was defined as the proportion of recombinants demon-
strating growth at each generation (cycle) analyzed.
Recombinants with growth in the third generation were
censored. The Kaplan-Meier analysis performed using
SAS v9.3 software (Cary, NC, USA) provides visual com-
parison of these survival distributions for the ALDHHi and
ALDHLow recombinants. The null hypothesis of no
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the Logrank test.
Results
Isolation of ALDHHi and ALDHLow cells from prostate cell
lines
The ALDEFLUOR™ assay was performed on RWPE-1
RWPE-2, CWR-R1 and DU-145 prostate cell lines.
ALDHHi cells represented 0.5 to 6% of the total cell popu-
lation in RWPE-1, RWPE-2, CWR-R1 and DU-145 pros-
tate cells (Figures 1A, C, E, G). ALDHHi cells are gated
based upon the absence of the population in the presence
of DEAB, an inhibitor of ALDH1, (Figures 1B, D, F, H)
and the ALDHLow cells were gated with a clear separation
from the ALDHHi cells (Figures 1A, C, E, G).Figure 1 Isolation of ALDHHi and ALDHLow cells from prostate cells by
cells were stained with ALDEFLUOR™ reagent and analyzed using BD FACS
gion (A, C, E and G). ALDHHi population was inhibited with DEAB resulting
is gated with a clear separation from the ALDHHi population.Prostate generation in recombinants with ALDHHi and
ALDHLow cells isolated from human prostate specimens
The ALDEFLUOR™ assay was performed on six radical
prostatectomy specimens. ALDHHi cells represented
0.6 to 4% of the cells in non-tumor, tumor and mixed
prostate specimens (Figure 2 and Table 1). ALDHHi or
ALDHLow cells were recombined with rUGMs in the tis-
sue recombinant assay in order to functionally test for
stem cell properties. Sorted cells suspended in collagen
without rUGM were used as a non-inductive control to test
tumorigenic capacity. Equal numbers of cells (50 to 2,000)
were used for each sorted population (Table 2). At the end
of each grafting period, the grafts were harvested, weighed
and examined microscopically, blinded to the contributing
population, for glandular formation. Recombinants thatALDEFLUOR™ assay. RWPE-1, RWPE-2, CWR-R1 and DU-145 prostate
Aria II sorter. ALDHHi cells were detected in the higher fluorescent re-
in no ALDHHi cell detection (B, D, F and H). The ALDHLow population
Figure 2 Isolation of ALDHHi and ALDHLow cells from clinical human prostate specimen by ALDEFLUOR™ assay. Cells isolated from
clinical human prostate specimen were stained with ALDEFLUOR™ reagent and analyzed using BD FACS Aria II sorter. ALDHHi cells were detected
in the higher fluorescent region (A, C and E). ALDHHi population was inhibited with DEAB resulting in no ALDHHi cell detection (B, D and F).
ALDHLow population is gated with a clear separation from the ALDHHi population.
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a small portion (approximately 1 mm3) of the ductal
structure was recombined with new rUGM and im-
planted under the renal capsule of host mice. The
remaining portion of each recombinant was formalin-
fixed and paraffin-embedded for IHC analysis. If under
the dissecting microscope there was no evidence of
ductal growth or the ductal growth was obviously
rodent, the recombinant was processed for histological
analysis of microscopic ductal growth, and no serial
recombination with rUGM was performed. This procedure
resulted in some recombinants with histological growth not
being serially passed and some recombinants being serially
passed, although there was no histological evidence of
human epithelial cell growth.Survival rate and number of human prostate glands
generated by recombinants
All recombinants were stained with H&E to evaluate
prostatic gland structure. Rodent telomere repeats were
used to identify rodent epithelial cell contribution to the
prostatic glands in the recombinants. Each recombinant
was examined for expression of rodent telomere repeat
with FISH analysis (Additional file 1: Figure S1). Prostate
glands that were negative for rodent telomeres were
considered to be of human origin [29]. First generation
growth was analyzed in 83 recombinants, in the first
generation 14/42 (approximately 33%) ALDHHi recombi-
nants and 10/41 (approximately 24%) ALDHLow recom-
binants contained human epithelial ductal growth, but
the difference was not statistically significant (Table 2,
Table 1 Viable ALDHHi, ALDHLow, side population and non-side population cells in human prostate tissue specimens
Specimen Gleason grade Specimen weight (g) # Viable cells % Viable cells % ALDHHi % ALDHLow
1NT 3 + 4 2.994 3.31 × 105 22.3 3.2 13.7
1 T 3 + 4 1.451 6.47 × 105 26.6 4.0 14.9
2NT 3 + 3 6.105 1.03 × 106 15.8 1.3 11.2
3NT 4 + 3 1.678 1.78 × 105 10.5 1.0 2.2
4 M 4 + 5 1.540 0.55 × 105 22.4 1.1 2.1
4 T 5.387 1.57 × 105 36.5 0.6 8.2
5NT 4 + 3 3.314 1.18 × 105 33.6 1.0 1.4
6 T 5 + 4 0.977 1.84 × 105 27.5 1.0 22.2
%SP %NSP
5NT 4 + 3 3.314 0.81 × 105 59.5 0.3 16.7
6 T 5 + 4 0.977 0.66 × 105 11.0 0.3 2.1
M, Mixed prostate specimen from radical prostatectomies; NSP, Non-Side Population; NT, Histologically non-tumor areas; SP, Side Population; T, Histologically
tumor areas. Percentage, percent of sorted populations was calculated based upon total viable cells from each specimen.
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genitourinary pathologist (GA) and was considered be-
nign. There was no evidence of prostate cancer pathology
in any of the specimens regardless of the pathology of the
initial tissue used. All recombinants were stained with
alpha-methylacyl-CoA racemace (AMACR), a marker of
prostate cancer and prostatic intraepithelial neoplasia and
no recombinants had detectable expression of AMACRTable 2 Incidence of ductal growth in ALDHHi and
ALDHLow recombinants
Prostate Ductal Growth(#Analyzed)[Weeks Grafted]
ALDHHi Generation ALDHLow Generation
Specimen # of Cells 1st 2nd 3rd 1st 2nd 3rd
1NT 250 0(3)[7] 1(3)[7] 1(1)[10]
1NT 1,000 1(3)[7] 1(1)[10] 1(1)[9] 1(3)[7] 1(3)[10]
1T 250 1(3)[7] 1(1)[10] 1(1)[9] 0(3)[7]
1T 1,000 2(3)[7] 2(2)[10] 0(1)[7]
2NT 2,000 2(3)[7] 2(2)[10] 1(1)[9] 1(2)[7] 1(1)[10]
3NT 500 1(3)[10] 1(1)[9] 2(3)[10] 1(2)[9]
3NT 2,000 1(3)[10] 0(1)[9] 1(3)[10] 1(1)[9]
4M 250 0(3)[10] 2(3)[7] 0(2)[8]
4M 1,000 2(3)[7] 0(2)[8] 0(3)[7]
4T 50 0(3)[7] 1(3)[7]
4T 250 0(3)[7] 0(3)[7]
5NT 50 0(3)[12] 0(3)[12]
5NT 250 1(2)[12] 1(1)[12] 1(2)[12] 1(1)[12]
6T 250 1(2)[8] 0(1)[6] 0(3)[8]
6T 500 2(2)[8] 0(3)[8]
Total 14(42) 8(12) 3(3) 10(41) 6(11)
NT: Histologically non-tumor areas; T: Histologically tumor areas; M: Mixed
prostate specimen from radical prostatectomies.(data not shown). The total number of human prostatic
glands in each first generation recombinant was deter-
mined (Figure 3B), but there was no significant difference
in the average number of human prostatic glands in
recombinants generated with ALDHHi cells compared to
ALDHLow cells.
The number of ALDHLow sorted cells used in tissue re-
combination or the length of engraftment did not seem to
impact the frequency of ductal growth in the recombi-
nants (Table 3). However, when 500 to 2,000 ALDHHi cells
were used in recombination, the ductal growth rate in-
creased to 50 to 60% compared to 0% to 19% when 50 to
250 ALDHHi cells were used (Table 3). Recombinants with
a minimum of 250 ALDHHi cells serially generated pros-
tate up to three generations, whereas no recombinant with
ALDHLow cells generated prostate ductal growth in the
third generation (Table 3). The frequency of recombinant
growth in the second and third generations was calculated
as a percentage of the initial number of recombinants
grafted in the first generation (Table 3).
The ability of the ALDHHi and ALDHLow cells to gen-
erate prostatic tissue in serial generations was compared
using Kaplan-Meier methods and was not statistically
significant P = 0.389 (Figure 3C). When recombinants
were harvested there was no definitive way to determine
the species of origin of the ductal growth in the recom-
binants. Therefore, serial passage of recombinants was
only performed when non-rodent ductal growth was evi-
dent upon micro-dissection. This resulted in instances
when recombinants that demonstrated histological hu-
man epithelial growth were not recombined and other
occasions where the ductal growth that was serially pas-
saged did not contain human epithelium upon his-
tological and FISH analysis. These recombinants were
removed from analysis if human ductal growth was not
Figure 3 Number of human prostate glands generated per recombinant and recombinant survival rate of recombinants grafted. A. The
percentage of recombinants with human ductal growth in the first generation ALDHHi n = 42 and ALDHLow n = 41, analyzed by Fisher’s Exact
test P = 0.4692. B. The number of glands per recombinant in the first generation derived from ALDHHi cells (n = 6) and ALDHLow (n = 5) was
quantitated and analyzed by unpaired t-test analysis P = 0.2558. C. Kaplan-Meier plot of recombinant survival rate in multiple generations, Logrank
test P = 0.3890.
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detected in the second and/or third generation recombi-
nants, human ductal growth was assumed in previous
generations even if not histologically detected in the
remaining portion not used for serial recombination.
ALDHHi and ALDHLow recombinants grafted under the
renal capsule of SCID mice generated differentiated
human prostate glands
All recombinants with human prostatic growth were
analyzed for prostate differentiation markers. Prostate
differentiation was tested by examining expression of
p63, AR, PSA, ALDH1A1, ABCG2 and chromogranin
A. Most glands contained cells expressing p63 and ARTable 3 Human ductal growth in each generation of
ALDHHi and ALDHLow recombinants
Number of recombinants with ductal growth (%)
# of
cells
N = # of
grafts
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0(Figure 4B, C). Recombinants generated from ALDHHi
cells were more likely to contain cells also expressing
ALDH1A1, PSA, ABCG2 or chromogranin A (Table 4). A
recombinant generated with 2,000 ALDHHi cells from 3
NT (Table 1) had cells positive for all markers examined
(Figure 4). High ALDH1A1 expression was observed in
few recombinants in isolated cells outside the p63 express-
ing basal layer (Figure 4F).
Nineteen percent of the ALDHHi recombinants con-
tained ALDH1A1 expressing cells within prostatic glan-
dular structure compared to only approximately 2% of
ALDHLow recombinants (Table 4). Thus, results from
tissue recombinant experiments showed that ALDHHi
cells serially generated prostate tissue, and ALDH1A1
expressing cells are retained in the prostatic growth pro-
viding evidence of self-renewal.
Inhibition of ALDH and ABCG2 activity decreases the
sphere-forming capability of prostate cancer cells
To determine the requirement of ALDH function in stem
cell maintenance, sphere formation capabilities were
tested in the presence and absence of DEAB, an ALDH1
inhibitor. Sphere formation capability of RWPE-2, CWR-
R1 and DU-145 prostate cells was detected upon inhib-
ition of ALDH by DEAB. RWPE-1 cells did not form
spheres (data not shown). Though sphere formation was
significantly decreased in the CWR-R1 cells upon inhib-
ition of ALDH activity (Figure 5C), sphere formation was
not decreased in either RWPE-2 (Figure 5A) or DU-145
(Figure 5E) prostate cells. RWPE-2 had the highest per-
centage of ALDHHi cells (Figure 1C) suggesting ALDH ac-
tivity may not be important in stem cell function.
The side population assay is another functional assay
used to isolate stem cells. For comparison, ABCG2 function
Figure 4 IHC analysis of prostate differentiation markers in a recombinant using 2,000 ALDHHi cells. IHC analysis of prostate differentiation
markers in a recombinant using 2,000 ALDHHi cells: A. H & E staining; B. p63 IHC; C. AR IHC; D. PSA IHC; E. ALDH1A1 IHC; F. Higher magnification of
boxed area of ALDH1A1 IHC in E; G. ABCG2 IHC; H. Higher magnification of boxed area of ABCG2 IHC in G; I. Chromogranin A (Chr A) IHC; J. Higher
magnification of Chromogranin A IHC in a different region of same recombinant. Arrow indicates positive cell. Scale bar = 50 μm.
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formation was significantly decreased in both RWPE-2
(Figure 5B) and CWR-R1 cells (Figure 5D) upon inhibition
of ABCG2 activity. Sphere formation was not altered in
DU-145 cells (Figure 5F) indicating AR may be required
for ABCG2 regulation of stem cell maintenance. Taken to-
gether ALDH activity represents a marker of prostate stem
cells but ALDH activity may not be required for stem cell
maintenance.Gene expression in cells isolated by stem cell functional
assays
Real-time PCR was performed on CWR-R1 cells iso-
lated by the ALDEFLUOR™ and side population assays
to determine the expression of ABCG2 and specific
ALDH isoforms. The CWR-R1 cell line was chosen be-
cause sphere formation depended on both ALDH and
ABCG2 activity. ABCG2 expression was approximately
five-fold higher in the side population compared to the
Table 4 Expression frequency of human prostate







ALDH1A1 8/42 (19%) 1/41 (2.4%)
PSA 14/42 (33.3%) 6/41 (14.6%)
ABCG2 19/42 (45.2%) 12/41 (29.2%)
Chromogranin
A
3/42 (7.1%) 1/41 (2.4%)
p63 42/42 (100%) 41/41 (100%)
AR 42/42 (100%) 41/41 (100%)
Figure 5 Sphere formation assay. RWPE-2, CWR-R1, and DU-145 prostate
Ko143 at 1 and 5 μM concentration or vehicle control. Spheres were count
of RWPE-2 cells did not decrease upon treatment with DEAB (A). Sphere fo
5 μM concentration (B). Sphere formation was decreased in CWR-R1 cells u
DU-145 cells did not decrease upon treatment with DEAB (E) or Ko143 (F).
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lects for cells with high ABCG2 expression (Figure 6A).
ALDH1A1 gene expression was approximately 30-fold
higher in ALDHHi cells compared to ALDHLow cells in-
dicating the ALDEFLUOR™ assay enriches for cells with
high ALDH1A1 expression (Figure 6B). The expression
of ALDH4A1, ALDH7A1 and ALDH9A1 genes was not
significantly altered either the side or ALDH popula-
tions (Figure 6A, B). Additionally, ALDH1A1 gene ex-
pression was higher in non-side population cells
compared to the side population (Figure 6A). Thus the
ALDEFLUOR™ assay does not select for cells expressing
ABCG2 and side population assay does not select for
cells with expressing ALDH1A1.cells were treated in the presence of DEAB at 5, 10 and 20 μM or
ed in each well after 10 to 14 days of growth. Sphere forming ability
rmation was decreased in RWPE-2 cells upon treatment with Ko143 at
pon treatment with DEAB (C) or Ko143 (D). Sphere forming ability of
Figure 6 Gene expression in ALDHHi, ALDHLow, side population, and non-side population cells isolated from CWR-R1 cells. ABCG2,
ALDH1A1, ALDH4A1, ALDH7A1 and ALDH9A1 gene expression was detected by real-time PCR in CWR-R1 cells isolated by the side population
and ALDEFLUOR™ assays. Gene expression was normalized to GAPDH and fold change in gene expression in each population was calculated
based on the formula: 2-(ΔΔdCt). ABCG2 expression was the highest in the side population with 5.4-fold increase compared to non-side population
(A), whereas ALDH1A1 expression was highest in NSP (A) and ALDHHi cells (B). Approximately 26-fold and 30-fold increase in ALDH1A1 gene
expression was observed in NSP (A) and ALDHHi cells (B) respectively as compared to their counter populations. Expression of ALDH4A1, ALDH7A1
and ALDH9A1 genes was not significantly different in any of the populations (A and B). NSP, Non-Side Population; SP, Side Population.
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and side population assays
To compare stem cell properties of cells sorted based
upon the ALDEFLUOR™ or the side population assays,
cells were isolated from the same clinical specimens
using either assays. Single viable cells from two radical
prostatectomy specimens were analyzed with ALDE-
FLUOR™ and side population assays. The ALDHHi and
ALDHLow cells and side and non-side population cells
were isolated from specimens 5NT and 6 T by FACS
(Figure 7 and Table 1) and used in tissue recombination.
Recombinants with as low as 50 side population cells
could serially generate human prostate tissue for two gen-
erations (Table 5). Recombinants with a minimum of 250
ALDHHi cells isolated from the same clinical specimen
were required to generate human prostate tissue when
serially recombined for two generations (Table 5). Third
generation growth was not detected in either population
(data not shown). The difference in the efficiencies of
prostatic ductal growth in recombinants with ALDHHi
and side population cells is intriguing but needs to be fur-
ther investigated to determine if one assay is more efficient
at enriching stem cells compared to the other.
Discussion
In the current study, we have analyzed the stem cell
properties of cells with high ALDH activity with the
ALDEFLUOR™ assay and the role of ALDH in stem cell
maintenance. Additionally, we have compared the stem
cell properties of cells isolated with the ALDEFLUOR™
assay to cells isolated based upon ABCG2 activity, with
the side population assay. The requirement for ALDHand ABCG2 activity for stem cell properties was evalu-
ated in tumorigenic prostate cell lines by determining
sphere forming capability when ALDH is inhibited by
DEAB or ABCG2 is inhibited by Ko143.
As few as 250 ALDHHi cells from freshly digested and
sorted clinical human prostate specimens recombined with
rUGM generated prostate tissue for three generations. The
serial prostate regenerative capability of ALDHHi cells in-
creased when higher numbers (500 to 2,000 ALDHHi cells)
were used in tissue recombination assays. Similarly, studies
using breast and prostate cancer cell lines showed low
tumor growth frequency using 500 ALDHHi cells, and
tumor growth frequency was increased when higher
numbers (5 × 104 to 1 × 105) of ALDHHi cells were used
[8,18,30,31]. Furthermore, only tumors derived from
ALDHHi PC-3 cells are composed of both ALDHHi and
ALDHLow cells demonstrating differentiation capability
[18]. The percentage of ALDHHi cells obtained in our stud-
ies in RWPE-1, RWPE-2, CWR-R1 and DU-145 prostate
cell lines ranged from 0.5 to 6%. These ranges are consist-
ent with previous studies with PC-3 and LNCaP prostate
cell lines [18]. We identified side populations in RWPE-2
(0.4%) (Additional file 3: Figure S3), and previously we have
identified the side population in RWPE-1 (0.04%), CWR-
R1 (0.4%) and DU-145 (0.73%) cell lines [22]. The percent-
age of cells in the side population is lower in most cell
lines, except in the androgen insensitive DU-145 cell line.
Thus, the side population appears to be more selective
compared to the ALDEFLUOR™ assay in prostate cell lines.
Real-time PCR analysis indicates that ABCG2 expressing
cells are not enriched in the ALDHHi population, and
ALDH1A1 expression is not enriched in the side population
Figure 7 Isolation of ALDHHi, ALDHLow, side population and non-side population cells from clinical human prostate specimen. Cells
isolated from clinical human prostate specimen were stained with either DCV or ALDEFLUOR™ reagent. The ALDHHi cells were detected in the
higher fluorescent region (A). ALDHHi population was inhibited with DEAB resulting in no ALDHHi cell detection (B). Side population was gated
based upon its absence in the presence of FTC, a specific inhibitor of ABCG2 (C and D).
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were different populations. Both functional assays were
not performed simultaneously because the assays are not
compatible [2]. This is in contrast to the hematopoietic
system, wherein quiescent CD34+CD38Low side populationTable 5 Incidence of ductal growth in ALDHHi, ALDHLow, side
Prostate Ductal Growth(#A
1st gen
Specimen # of Cells ALDHHi ALDHLow SP
5NT 50 0(3) [12] 0(3) [12] 2(3) [12]
5NT 250 1(2) [12] 1(2) [12]
6 T 125 0(2) [8]
6 T 250 1(2) [8] 0(3) [8] 0(2) [8]
6 T 500 2(2) [8] 0(3) [8]
Total 4(9) 1(11) 2(7)
NT, Histologically non-tumor areas; T, Histologically tumor areas from radical prostacells were highest in the ALDHHi population, and the
combination of assays produces the most enriched primi-
tive hematopoietic stem/progenitor cell population [32].
The sphere formation assay has been shown as an
in vitro correlate to test for the presence of stem cellspopulation and non-side population recombinants
nalyzed)[weeks grafted]
eration 2nd generation
NSP ALDHHi ALDHLow SP NSP
2(3) [12] 1(2) [15] 2(2) [15]
1(1) [12] 1(1) [12]
1(3) [8] 0(1) [6]
0(3) [8] 0(1) [6]
3(9) 1(2) 1(1) 1(2) 2(3)
tectomies; SP, Side Population; NSP, Non-Side Population.
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lines have more sphere-forming and tumorigenicity cap-
ability compared to ALDHLow cells [18-20,30,31,33,34].
Sphere formation decreased in CWR-R1 cells upon
treatment with DEAB, suggesting that ALDH activity is
important for maintaining stem cell properties in CWR-
R1 prostate cells. Sphere-forming ability of RWPE-2 and
DU-145 prostate cells did not decrease upon treatment
with DEAB. Concurrently, we tested the requirement of
ABCG2 activity for sphere formation using Ko143, an
ABCG2 specific inhibitor. ABCG2 activity is required for
the formation of spheres in RWPE-2 and CWR-R1 pros-
tate cells. However, the sphere-forming ability of androgen
insensitive DU-145 prostate cells did not decrease upon
treatment with Ko143, suggesting the requirement of an-
drogen signaling for ABCG2 dependent stem cell proper-
ties. ABCG2 mediated androgen efflux regulates nuclear
AR expression [35]. Thus, ABCG2 activity in AR deficient
cells may not be required for stem cell properties.
Recombinants with ALDHHi cells had human ductal
growth in the first generation at a high frequency, and
each recombinant contained a high number of glands
compared to the recombinants generated with ALDHLow
cells. Results from IHC analysis showed that ALDHHi
recombinants contained ALDH1A1 expressing cells, thus
demonstrating self-renewal capabilities, nuclear AR and
the basal cell marker p63. Additionally, ALDH1A1 expres-
sion was also detected in non-basal cells in the recombi-
nants as illustrated by cytoplasmic staining. An ALDHHi
recombinant showed that ALDH1A1 positive glands also
expressed ABCG2, PSA and chromogranin A. These
results suggest that ALDH1A1 is expressed in heteroge-
neous, cells with multipotency, some of which possess
stem cells properties. As further evidence of differentiation
potential, a higher percent of ALDHHi recombinants with
human ductal growth expressed ALDH1A1, ABCG2 and
PSA with 19%, 45% and 33% recombinants showing ex-
pression, respectively, compared to 2%, 29% and 15%, re-
spectively, in ALDHLow recombinants (Table 4).
None of the recombinants suspended in collagen alone
grew prostatic tissue and recombinants with rUGM did not
demonstrate prostate cancer pathology. This is not surpri-
sing since the presence of an inductive microenvironment,
provided by the rUGM in these experiments, has been
shown to be critical to trigger prostate generation [36,37].
Previous studies have shown that the presence of inductive
mesenchyme can normalize transformed epithelial cells gi-
ving rise to normal prostatic growth even from cells isolated
from tumor specimens [38-40]. Alternatively, prostate can-
cer pathology was observed in the tissue recombination
assay with rUGM when a high number of prostate cancer
cells were used [37]. There could be several possibilities for
why no cancer pathology was found in the recombinants
using cells isolated based on either the ALDEFLUOR™ orside population assays. Several studies used prostate cancer
cell lines, increasing the possibility of isolating cancer stem
cells. The number of cells used in this study, 50 to 2,000,
may not be enough to implant the rare cancer stem cell.
There could also be patient variability with respect to the
presence of cancer stem cell markers accounting for the
presence of fewer side populations or ALDHHi cells in dif-
ferent specimens. Alternatively, there could be cancer stem
cells expressing different markers, other than ABCG2 or
ALDH activity, that have the capability to initiate prostate
tumor growth. Prostate cancer stem cells from human spec-
imens capable of forming prostate tumor pathology in the
recombination assay were not isolated by the side popula-
tion or ALDEFLUOR™ assays. Nevertheless, results from the
tissue recombination assay showed that there is serial trans-
plantable and prostate regenerative capability in recombi-
nants with side population and ALDHHi cells.
Previous reports from our laboratory have identified side
population cells in different prostate cell lines and freshly
digested human prostate specimens [22,26]. Furthermore,
side population cells isolated from human prostate speci-
mens generated prostatic tissue for multiple generations in
the tissue recombination assay [26]. Therefore, we wanted
to directly compare putative prostate stem cells isolated
based upon ABCG2 or ALDH activity. Since, the ALDH
product formed in the ALDEFLUOR™ reaction is effluxed
by the ABCG2 transporter [2], the side population and the
ALDEFLUOR™ assays were performed separately. The spe-
cimens contained 1% ALDHHi cells and about 0.3% of the
cells in the specimens demonstrated the side population
phenotype. Results from the tissue recombination assay with
side population cells are consistent with our previous stu-
dies [26]. In our current study, we have observed serial ge-
neration of prostate growth with as low as 250 ALDHHi and
50 side population cells. While recombinants with as low as
50 side population cells generated prostate for two genera-
tions, a minimum of 250 ALDHHi cells were required to seri-
ally generate prostate for two generations. Results from the
tissue recombinant assay comparing the prostate regeneration
capability of side population and ALDHHi cells suggested that
a higher percentage of cells with ABCG2 activity have stem
cell potential compared to cells with high ALDH activity.
Conclusions
This is the first study to demonstrate that ALDHHi cells
isolated from human prostate tissue demonstrate pros-
tate tissue growth in the tissue recombination assay.
Cells isolated based on ABCG2 activity have a higher
frequency of stem cell potential compared to ALDHHi
cells and the ALDEFLUOR™ assay does not enrich
for ABCG2 expressing cells. The ALDEFLUOR™ assay
does isolate prostate stem cells, but the side population
assay enriches for prostate cells with more stem cell
potential.
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Additional file 1: Figure S1. Positive and negative controls for
telomere FISH analysis. Mouse control tissue A. Telomere FISH analysis
positive for telomere repeats; B. DAPI counter stain same field; Human
control tissue C. Telomere FISH analysis negative for telomere repeats;
D. DAPI counter stain same field. Scale bar = 10 μm.
Additional file 2: Figure S2. Positive and negative human prostate
controls for IHC staining. A. p63 IHC; B. no primary antibody (p63) with
goat anti-mouse IgG antibody IHC; C. AR IHC; D. no primary antibody
(AR) with goat anti-rabbit IgG antibody IHC; E. PSA IHC; F. no primary
antibody (PSA) with goat anti-mouse IgG antibody IHC; G. ABCG2 IHC;
H. no primary antibody (ABCG2) with goat anti-mouse IgG antibody IHC;
I. Chromogranin A IHC; J. no primary antibody (Chromogranin A) with goat
anti-rabbit IgG antibody IHC. K. ALDH1A1 IHC; L. no primary antibody
(ALDH1A1) with goat-anti-rabbit IgG antibody IHC. Scale bar = 50 μm.
Additional file 3: Figure S3. Isolation of side population and non-side
population cells from RWPE-2 prostate cells. RWPE-2 prostate cells were
stained with DCV reagent. The side population was gated based upon its
absence in the presence of FTC, a specific inhibitor of ABCG2 (A and B).Abbreviations
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